Abstract: A method for enhancing compressive strength of a lead smelting water-quenched slag-based cementitious material by mechanical activation is provided, belonging to the technical field of solid waste resource treatment. The method includes following steps: grinding and activating water-quenched slag from lead smelting, then mixing with calcium-based solid waste, magnesium-based solid waste, magnesium oxide, portland cement and water, and performing a steam curing and a curing at normal temperature on cementitious material slurry obtained to obtain the lead smelting water-quenched slag-based cementitious material.

Abstract: The present disclosure relates to a mixed matrix carbon molecular sieve (CMS) membrane, a preparation method of the mixed matrix CMS membrane, and use of the mixed matrix CMS membrane in C2H4/C2H6 separation, and belongs to the technical field of membrane separation. The present disclosure solves the problem that the CMS materials in the prior art exhibit low selectivity and low flux during an ethylene/ethane separation process. In this patent, C3N4 is used as a filling particle to prepare a mixed matrix membrane (MMM), and the MMM is pyrolyzed to prepare a CMS membrane. The C3N4/6FDA-DAM MMM has prominent C2 separation performance.

Abstract: The present disclosure relates to a mixed matrix carbon molecular sieve (CMS) membrane, a preparation method of the mixed matrix CMS membrane, and use of the mixed matrix CMS membrane in C2H4/C2H6 separation, and belongs to the technical field of membrane separation. The present disclosure solves the problem that the CMS materials in the prior art exhibit low selectivity and low flux during an ethylene/ethane separation process. In this patent, C3N4 is used as a filling particle to prepare a mixed matrix membrane (MMM), and the MMM is pyrolyzed to prepare a CMS membrane. The C3N4/6FDA-DAM MMM has prominent C2 separation performance.

Abstract: This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind Glycoprotein Ib alpha (GPIba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications. In some embodiments, the disclosure relates to the production, diagnostic use, and therapeutic use of monoclonal and polyclonal antibodies, and the antigen-binding fragments thereof, which specifically bind GPIba. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies for specific binding agent. Compositions and methods for inhibiting shedding, clearance, or degradation, or treating diseases associated with GPIba ectodomain shedding are also described.

Abstract: This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind Glycoprotein Ib alpha (GPIba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications. In some embodiments, the disclosure relates to the production, diagnostic use, and therapeutic use of monoclonal and polyclonal antibodies, and the antigen-binding fragments thereof, which specifically bind GPIba. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies for specific binding agent. Compositions and methods for inhibiting shedding, clearance, or degradation, or treating diseases associated with GPIba ectodomain shedding are also described.